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Abstract
Background and Objective The anti-oestrogen tamoxifen
requires metabolic activation to endoxifen by cytochrome
P450 (CYP) enzymes, predominantly CYP2D6. Potent
CYP2D6-inhibiting antidepressants can seriously disrupt
tamoxifen metabolism, probably influencing the efficacy of
tamoxifen. For this reason, paroxetine and fluoxetine are
recommended not to be used with tamoxifen in breast
cancer patients. We investigated the effects of switching
potent CYP2D6-inhibiting antidepressants to weak
CYP2D6-inhibiting antidepressants on the plasma phar-
macokinetics of tamoxifen.
Methods Ten breast cancer patients who were treated
with tamoxifen in combination with a potent CYP2D6-
inhibiting antidepressant (paroxetine or fluoxetine) for at
least 4 weeks were enrolled. Under close supervision by a
psychiatrist, patients were switched to treatment with esc-
italopram or venlafaxine (weak CYP2D6-inhibiting
antidepressants). Before and after the switch, pharma-
cokinetic blood sampling was performed over 24 h. Phar-
macokinetic parameters were estimated using
noncompartmental analysis. Adverse effects were recorded
during the study.
Results Endoxifen exposure was *3-fold higher during
escitalopram co-administration than during paroxetine or
fluoxetine co-administration (median 387 nMh [range
159–637 nMh] versus 99.2 nMh [range 70.0–210 nMh];
P = 0.012; Wilcoxon signed-rank test). The ratio of
endoxifen to N-desmethyltamoxifen and the ratio of 4-hy-
droxytamoxifen to tamoxifen increased by 3.3- and *1.5-
fold, reflecting increased CYP2D6 activity. Antidepressant
switching did not result in psychiatric problems or
antidepressant-related adverse effects.
Conclusion In this study, switching to the weak CYP2D6
inhibitor escitalopram was safe and feasible and resulted in
clinically relevant rises in endoxifen concentrations. We
therefore advise switching paroxetine and fluoxetine to
escitalopram in patients using tamoxifen. However,
switching should always be weighed in individual patients.
This work was presented at the ESMO Annual Meeting; September
26–30, 2014; Madrid, Spain.
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Key Points
Switching from potent cytochrome P450 (CYP)
2D6-inhibiting antidepressants to a weak CYP2D6-
inhibiting antidepressant resulted in relevant rises in
endoxifen systemic exposures in breast cancer
patients.
The weak CYP2D6 inhibitor escitalopram seems to
be a safe alternative in tamoxifen-treated patients
requiring treatment with an antidepressant.
The potent CYP2D6-inhibiting antidepressants
paroxetine and fluoxetine should be switched to
escitalopram in tamoxifen-treated individuals.
1 Introduction
Tamoxifen, a selective oestrogen receptor modulator, is the
standard endocrine treatment for premenopausal women
with hormone-sensitive breast cancer. In sequence with
aromatase inhibitors, or as an alternative to aromatase
inhibitors, tamoxifen can be given to postmenopausal
women [1]. Tamoxifen reduces the 15-year risk of recur-
rence and breast cancer death in patients with early disease
and prolongs survival in the metastatic setting. However,
recurrence of disease and disease progression are observed
in a substantial proportion of patients. Resistance to
tamoxifen may be attributable to variability in exposure to
the active metabolite [2, 3].
Tamoxifen is a pro-drug and undergoes metabolic acti-
vation to 4-hydroxytamoxifen and endoxifen. First, tamox-
ifen is metabolized to its primary metabolites, N-
desmethyltamoxifen and 4-hydroxytamoxifen, catalysed by
several cytochrome P450 (CYP) enzymes, including
CYP3A, CYP2C9/19 and CYP2D6. Both primary metabo-
lites can bemetabolized to endoxifen. CYP3A and CYP2C9/
19 are the main enzymes involved in the conversion of
4-hydroxytamoxifen to endoxifen, and CYP2D6 is the main
enzyme for the conversion of N-desmethyltamoxifen to
endoxifen [4, 5]. Endoxifen is considered to be the principal
active metabolite of tamoxifen, and systemic concentrations
of this metabolite probably need to exceed a threshold level
for clinical efficacy in women with breast cancer [6–8].
The CYP2D6 enzyme has a key role in the metabolism
of tamoxifen into endoxifen. It has been shown that
patients carrying variant alleles of CYP2D6 produce little
endoxifen [5, 9] and, although this has not consistently
been shown, they may have a poorer clinical outcome
[10–13]. CYP2D6-inhibiting medications may also inter-
fere with tamoxifen therapy by reducing endoxifen
concentrations. Selective serotonin reuptake inhibitors
(SSRIs) and selective serotonin and norepinephrine
reuptake inhibitors (SNRIs) are known to inhibit CYP2D6
to varying degrees. Because depressive disorder is com-
mon in breast cancer patients, but also for other indica-
tions, these antidepressant drugs are often co-prescribed
in tamoxifen-treated individuals [9, 14, 15]. Paroxetine
and fluoxetine are potent CYP2D6 inhibitors, which have
been shown to markedly reduce endoxifen formation [7,
9] and to negatively affect the clinical outcome in women
receiving tamoxifen [16, 17].
Venlafaxine and escitalopram have been proposed as
safer options in patients using tamoxifen, with respect to
their effects on endoxifen formation. Both drugs are weak
CYP2D6 inhibitors and may reduce endoxifen concentra-
tions only slightly [9, 14, 15]. However, an intra-patient
comparison is lacking so far. Therefore, we investigated
the effects of switching potent CYP2D6-inhibiting antide-
pressants to a weak CYP2D6-inhibiting alternative on the
plasma pharmacokinetics of tamoxifen and its metabolites
in breast cancer patients in a pharmacokinetic study.
2 Materials and Methods
2.1 Subjects
Women who were treated with 20 or 40 mg tamoxifen once
daily in combination with a potent CYP2D6-inhibiting
antidepressant (paroxetine or fluoxetine) for at least 4 weeks
were included in the study. Other inclusion criteria were age
[18 years; World Health Organization (WHO) performance
score\1; and adequate haematological, renal and hepatic
functions. The principal exclusion criteria were contra-indi-
cations for venlafaxine or escitalopram use, congenital long
QT syndrome or suicidal ideation. Concomitant use of med-
ications and/or supplements that could interactwith tamoxifen
or the antidepressant drugs was not allowed. Standard labo-
ratory tests and an electrocardiogram were performed before
the start of the study, and blood samples were obtained for
CYP2D6 genotype determination. Informed consent forms
were signed by all study participants before study entry, and
the Erasmus MC review board approved the study protocol
(Dutch Trial Registry; no. NTR3125).
2.2 Study Design
This was a prospective pharmacokinetic study designed to
investigate the effects of switching from potent CYP2D6-
inhibiting antidepressants (paroxetine or fluoxetine) to a
weak CYP2D6 inhibitor (venlafaxine or escitalopram) on
the plasma pharmacokinetics of tamoxifen and its
metabolites. The study was performed between November
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2011 and June 2014. Patients were asked to participate
during regular visits to the outpatient clinic.
Under careful supervision by a psychiatrist (MB),
patients were switched from paroxetine or fluoxetine to
treatment with escitalopram or venlafaxine. The antide-
pressant therapy was individually adjusted, and switching
strategies were supervised by the psychiatrist. Adverse
effects and the use of concomitant medication were
recorded by the patients during the study.
Once during concomitant use of tamoxifen and the
potent CYP2D6-inhibiting antidepressant, and once during
co-treatment with the weak CYP2D6 inhibitor, blood was
collected for pharmacokinetic analyses of tamoxifen and its
metabolites. The two periods were separated by an ade-
quate wash-out period (30–80 days after the antidepressant
switch, depending on the antidepressant). Since the switch
between the antidepressants required dose tapering, the
second day of blood sampling was dependent on the last
day of paroxetine/fluoxetine intake.
Laboratory tests were performed on both days of blood
sampling, and an additional electrocardiogram was
obtained during the second sampling day, because patients
were using the new antidepressant at that time.
2.3 Measurement of Tamoxifen and Its Main
Metabolites in Plasma
Blood samples (4 mL; lithium-heparin) for the measure-
ment of tamoxifen and its main metabolites were collected
just before and at 0.5, 1, 1.5, 2, 4, 6, 8, 12 and 24 h after
administration of tamoxifen. Plasma was isolated by cen-
trifugation of the samples for 10 min at 2500g and was
stored at -70 C until the analysis. The measurement of
tamoxifen and its main metabolites in plasma was per-
formed using a validated ultra-performance liquid chro-
matography (UPLC)–tandem mass spectrometry (MS/MS)
assay, as described elsewhere [18].
Individual pharmacokinetic parameters, including the
trough concentration (Ctrough) and maximum concentration
(Cmax), were determined, and the area under the plasma
concentration–time curve from time zero to 24 h (AUC0–24)
was calculated by noncompartmental analysis using Phoenix
WinNonlin 6.1 (Pharsight Corporation,MountainView,CA,
USA). The estimated parameters of patients who used 40 mg
tamoxifen were corrected to 20 mg. The metabolic ratios
were computed as AUC0–24 metabolite/AUC0–24 tamoxifen.
2.4 CYP2D6 Genotyping
Genomic DNA was isolated from whole blood, and geno-
type analyses for CYP2D6*3, *4, *6, *10, *17 and *41
were performed using TaqMan allelic discrimination
assays on an ABI Prism 7000 Sequence detection system
(Applied Biosystems, Foster City, CA, USA), and CYP2D6
gene deletion (*5) and duplication using a CYP2D6 Taq-
Man Gene Copy Number Assay.
2.5 Statistics
To detect a 25 % difference in the AUC0–24 of endoxifen
between co-administration of a potent CYP2D6 inhibitor
and a weak CYP2D6 inhibitor, with a two-sided 5 % sig-
nificance level and power of 80 %, 13 study participants
were required. This was based on a within-patient variation
of 20 % in the pharmacokinetics of endoxifen.
Pharmacokinetic data are presented as medians and
ranges. The differences in pharmacokinetic parameters,
before and after the switch, were evaluated using Wilcoxon
signed-rank tests for related samples. P values of B0.05
were regarded as statistically significant. Statistical tests
were performed using IBM SPSS statistics, version 21
(SPSS Inc., Chicago, IL, USA).
3 Results
Pharmacokinetic data were available for ten patients
(Table 1) [19, 20]. Because of problems with the blood
sampling for pharmacokinetic analysis, only Ctrough values
were available for two of these patients. Most women
received adjuvant tamoxifen at a dose of 20 mg. Two
women received a dose of 40 mg—one woman for meta-
static disease and one because of extreme overweight.
The women received antidepressants for the treatment of
depressive disorder (n = 6) or anxiety disorder (n = 4),
which was diagnosed before initiation of tamoxifen therapy.
Eight women used paroxetine at a dose ranging from 15 to
60 mg per day; twowomen received fluoxetine at doses of 20
and 30 mg, respectively. Nine women were switched to
escitalopram; seven patients received a dose of 10 mg per
day, and two patients received higher doses of 15 and 20 mg,
respectively, because of the nature of their conditions. By
mistake, one woman received citalopram (a weak CYP2D6
inhibitor) at a dose of 10 mg. None of the women received
venlafaxine. The ages of the study participants ranged from
41 to 62 years (median 51 years), and their body mass
indices varied from23.0 to 45.2 kg/m2 (median 30.0 kg/m2).
The pharmacokinetic parameters of tamoxifen and its
three main metabolites during co-administration of parox-
etine or fluoxetine and during escitalopram co-administra-
tion are listed in Table 2. Plasma concentration–time profiles
of tamoxifen and endoxifen and individual changes in
plasma exposures following the switch are shown in Fig. 1.
Following the switch from a potent CYP2D6-inhibiting
antidepressant to escitalopram, endoxifen plasma exposure
increased markedly from 99.2 nMh (range 70.0–210 nMh)
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to 387 nMh (range 159–637 nMh; P = 0.012). The Ctrough
and Cmax of endoxifen were also *3-fold higher during
escitalopram co-administration. The AUC0–24, Ctrough and
Cmax of 4-hydroxytamoxifen increased by 34 %
(P = 0.017), 40 % (P = 0.017) and 42 % (P = 0.036),
respectively, after the switch. However, the pharmacokinetic
parameters of tamoxifen and N-desmethyltamoxifen did not
differ significantly between tamoxifen co-administration
with paroxetine/fluoxetine and tamoxifen co-administration
with escitalopram.
Switching from a potent CYP2D6 inhibitor to a weak
CYP2D6 inhibitor resulted in a more than 3-fold higher
AUC0–24 ratio of endoxifen to N-desmethyltamoxifen and a
*1.5-fold higher ratio of 4-hydroxytamoxifen to tamox-
ifen ratio.
Adverse effects that were reported by the study partic-
ipants included hot flashes, insomnia, nausea and joint
pain. The adverse effects were mild and appeared not to be
associated with antidepressant use. However, following the
switch to the weak CYP2D6-inhibiting antidepressant, two
individuals reported an increase in the incidence of hot
flashes (up to twice as many periods of hot flashes per day),
and in one woman the severity of hot flashes was increased
(she suffered during a longer period from hot flashes).
4 Discussion
In this study, we evaluated for the first time whether
switching from paroxetine or fluoxetine to escitalopram
could increase endoxifen concentrations in women treated
with tamoxifen. We observed that exposure to the active
tamoxifen metabolites, particularly endoxifen, was con-
siderably higher during co-administration with escitalo-
pram than during concomitant use of paroxetine or
fluoxetine. Because of the lesser degree of CYP2D6
inhibition, or no inhibition at all, during concomitant use
of escitalopram, concentrations of 4-hydroxytamoxifen
and endoxifen increased. This is further supported by the
higher ratio of endoxifen to N-desmethyltamoxifen—and,
to a lesser extent, the ratio of 4-hydroxytamoxifen to
tamoxifen—during escitalopram co-administration,
reflecting higher CYP2D6 activity. Although the increase
in endoxifen exposure varied among the individuals,
probably because of differences in CYP2D6 genotypes,
even in women with the intermediate metabolizer geno-
type, endoxifen exposure increased following the SSRI
switch.
The extremely low endoxifen concentrations during
paroxetine co-administration were in line with previous
findings by Stearns et al. [7], although the endoxifen con-
centrations they reported were slightly higher than those
observed in our study. This observation is remarkable
because patients in the present study received a weak
CYP2D6-inhibiting antidepressant, whereas women in the
previous study did not receive any CYP2D6-inhibiting
medication concomitantly during the control phase [7].
This might be explained by the use of higher doses of
paroxetine ([15 mg per day) in the current study, resulting
in more potent CYP2D6 inhibition during paroxetine co-
administration [21]. Also, we observed higher 4-hydroxy-
tamoxifen concentrations after the switch.
Table 1 Patient characteristics
Patient Age
(years)
BMI
(kg/m2)
Tamoxifen
dose (mg)
Setting Mental disordera First antidepressant
and doseb
Second antidepressant
and dose
CYP2D6
genotype
1 43 24.1 20 Adjuvant Depressive disorder Paroxetine 15 mg Escitalopram 15 mg *1/*1 (EM)
2 54 23.0 20 Adjuvant Depressive disorder Paroxetine 60 mg Escitalopram 20 mg *1/*1 (EM)
3 49 32.9 20 Adjuvant Depressive disorder Paroxetine 20 mg Citalopram 10 mgc *1/*1 (EM)
4 43 29.4 20 Adjuvant Anxiety disorder Paroxetine 20 mg Escitalopram 10 mg *1/*4 (IM)
5 55 33.6 20 Adjuvant Anxiety disorder Fluoxetine 20 mg Escitalopram 10 mg *1/*1 (EM)
6d 48 45.2 40e Adjuvant Depressive disorder Paroxetine 20 mg Escitalopram 10 mg *1/*1 (EM)
7 59 26.4 20 Adjuvant Anxiety disorder Paroxetine 20 mg Escitalopram 10 mg NA
8 41 29.3 40 Metastatic Depressive disorder Fluoxetine 30 mg Escitalopram 10 mg *1/*1 (EM)
9 53 30.7 20 Adjuvant Anxiety disorder Paroxetine 40 mg Escitalopram 10 mg *4/*41 (IM)
10d 62 32.0 20 Adjuvant Depressive disorder Paroxetine 20 mg Escitalopram 10 mg *4/*41 (IM)
BMI body mass index, Ctrough trough concentration, CYP cytochrome P450, EM extensive metabolizer, IM intermediate metabolizer, NA not
available
a Diagnosed before initiation of tamoxifen therapy
b Paroxetine and fluoxetine are equally potent inhibitors of CYP2D6 [19]
c One woman received citalopram instead of escitalopram; however, the weak CYP2D6-inhibiting properties of the compounds are similar [20]
d Because of problems with blood sampling, only Ctrough values were available
e Based on a high BMI
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Effective treatment of depression or anxiety disorders
with antidepressants is vital for the disorder itself, and it
may also contribute to better adherence to tamoxifen [22].
Concomitant use of potent CYP2D6-inhibiting antide-
pressants with tamoxifen is discouraged. Antidepressants
with weak CYP2D6-inhibiting properties, such as esci-
talopram, have been recommended in tamoxifen-treated
patients [14]. We demonstrated that during co-adminis-
tration of escitalopram, women had endoxifen exposure
that was similar to that observed in a genotype-matched
cohort of tamoxifen-treated women not receiving
CYP2D6-inhibiting co-treatment [23, 24]. No increase in
the endoxifen Ctrough was observed in one woman fol-
lowing the switch. Besides having a CYP2D6 intermedi-
ate metabolizer genotype (CYP2D6*4/*41), this patient
was using other medications. Although no interacting
medications were allowed, the effects of the medications
used by that patient on the pharmacokinetics of tamoxifen
cannot be ruled out.
Although we found that escitalopram had little or no
effect on endoxifen formation, the effect on breast cancer
outcome is not completely clear. However, evidence sug-
gests that endoxifen exposure is a predictor of tamoxifen
efficacy. Madlensky et al. [8] reported a higher risk of
breast cancer recurrence in patients with endoxifen con-
centrations below a minimal threshold level (15 nM). In
our study, none of the women reached endoxifen concen-
trations above the proposed threshold concentration during
co-treatment with the potent CYP2D6-inhibiting antide-
pressant. During escitalopram co-administration, five
women with a CYP2D6 extensive metabolizer genotype
had endoxifen concentrations above the threshold. Three
women who did not reach endoxifen concentrations above
the threshold level after the switch had impaired CYP2D6
metabolism according to their genotype (intermediate
metabolizers; CYP2D6*4 allele). In one woman, the
observed endoxifen exposure was dose corrected, because
of the use of 40 mg tamoxifen instead of 20 mg. After the
Table 2 Effects of potent and weak cytochrome P450 (CYP) 2D6-inhibiting selective serotonin reuptake inhibitors (SSRIs) on tamoxifen
pharmacokinetics
Tamoxifen ? potent
CYP2D6-inhibiting SSRI
Tamoxifen ? weak
CYP2D6-inhibiting SSRI
Ratio of weak to potent
CYP2D6-inhibiting SSRI
P valuea
Tamoxifen
Cmax (nM) 369 (189–667) 366 (177–516) 0.97 (0.67–1.29) 0.889
Ctrough (nM)
b 278 (128–557) 290 (123–375) 0.95 (0.67–1.38) 0.575
AUC0–24 (nMh) 6422 (3574–12,182) 6958 (3226–9567) 0.98 (0.79–1.18) 0.674
ND-Tam
Cmax (nM) 528 (395–977) 631 (365–955) 1.09 (0.77–1.75) 0.484
Ctrough (nM)
b 446 (306–807) 560 (312–704) 0.97 (0.76–1.37) 0.953
AUC0–24 (nMh) 10,149 (7744–20,107) 11,500 (7441–16,113) 1.09 (0.75–1.27) 0.674
4-OH-Tam
Cmax (nM) 3.46 (1.36–4.95) 4.09 (2.42–8.25) 1.42 (0.81–2.05) 0.036
Ctrough (nM)
b 2.47 (1.29–4.65) 3.25 (1.99–6.06) 1.40 (0.82–2.06) 0.017
AUC0–24 (nMh) 63.8 (27.4–98.2) 85.8 (51.1–148) 1.34 (0.88–1.87) 0.017
Endoxifen
Cmax (nM) 5.46 (3.86–11.1) 23.1 (9.05–33.2) 2.96 (1.50–7.44) 0.012
Ctrough (nM)
b 5.20 (3.48–10.6) 16.3 (7.05–30.8) 2.80 (1.02–6.33) 0.005
AUC0–24 (nMh) 99.2 (70.0–210) 387 (159–637) 2.98 (1.67–6.82) 0.012
Ratios
Endoxifen to ND-Tam 0.0113 (0.0065–0.014) 0.0311 (0.018–0.057) 3.33 (1.56–5.37) 0.012
4-OH-Tam to tamoxifen 0.0109 (0.0053–0.014) 0.0149 (0.0084–0.020) 1.51 (1.08–1.67) 0.012
Endoxifen to tamoxifen 0.0213 (0.0057–0.029) 0.0559 (0.034–0.10) 2.85 (1.96–6.42) 0.012
Potent CYP2D6-inhibiting SSRIs: paroxetine or fluoxetine; weak CYP2D6-inhibiting SSRIs: escitalopram (and, in one woman, citalopram)
Data are presented as median (range)
The parameters of one patient were dose corrected to 20 mg
4-OH-Tam 4-hydroxytamoxifen, AUC0–24 area under the curve from 0 to 24 h, Cmax maximum concentration, Ctrough concentration before
dosing, ND-Tam N-desmethyltamoxifen
a Wilcoxon signed-rank test
b Ctrough data from 10 patients; the parameters of two patients were dose corrected to 20 mg
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switch, endoxifen exposure was 2.9-fold higher in this
patient, and the measured endoxifen Ctrough was well above
the threshold concentration. The low endoxifen exposure in
the other woman cannot be explained by her CYP2D6
genotype or other known factors. Despite 1.8-fold higher
endoxifen concentrations following the switch, the
endoxifen levels did not exceed the threshold concentra-
tion. Given that after the switch, women had still endoxifen
concentrations below the threshold level, this indicates that
therapeutic drug monitoring may be an important tool to
individualize and optimize tamoxifen therapy.
Although this study was not designed to detect differ-
ences in side effects, it is interesting to note that hot flashes
were reported particularly during escitalopram co-admin-
istration, which may have been due to higher endoxifen
levels [25]. Few studies have investigated the relationship
between endoxifen concentrations and hot flashes, and they
reported contradictory results [25, 26]. This finding might
also have been due to differences in the effectiveness of
paroxetine/fluoxetine and escitalopram in treating hot fla-
shes. None of the ten women had to discontinue escitalo-
pram treatment.
Individuals were switched to escitalopram (10–20 mg/day);
none of the patients received venlafaxine. Women were
successfully switched, using cross-tapering, under careful
supervision by an experienced psychiatrist. No antide-
pressant-related adverse events or psychiatric relapse were
noted. However, although switching from paroxetine/flu-
oxetine to escitalopram was safe in this study, to ensure
effective antidepressant treatment, switching should always
be weighed in individual patients.
A limitation of the study might have been the small
sample size; however, the results were unequivocal. Lack of
adherence to tamoxifen or the antidepressant therapy might
have influenced the results of the study. In addition, steady-
state levels of tamoxifen metabolites were not reached in all
patients, because not all women used tamoxifen for
4 months [27]. A period of 4 months to reach steady state
has been suggested by Jin et al. [27]. However, steady-state
levels may be reached after 2 months, on the basis of the
14-day half-life of the primary metabolite. In addition, this
may have contributed to only small differences in the con-
centrations of tamoxifen metabolites.
5 Conclusion
Escitalopram seems to be a safe alternative in tamoxifen-
treated patients requiring antidepressants. Clinically rele-
vant increases in endoxifen exposure were observed fol-
lowing the switch to escitalopram. We strongly recommend
switching paroxetine and fluoxetine to escitalopram in
tamoxifen-treated breast cancer patients.
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Fig. 1 Individual changes in trough concentration (Ctrough) values for
a tamoxifen and b endoxifen following the switch from a potent
cytochrome P450 (CYP) 2D6-inhibiting antidepressant (paroxetine
[Parox] or fluoxetine [Fluox]) to a weak CYP2D6-inhibiting antide-
pressant (escitalopram), and mean plasma concentration–time profiles
for c tamoxifen and d endoxifen during concomitant use of paroxetine
or fluoxetine (white circles) and during concomitant use of escitalo-
pram (black circles)
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